

Special Issue

Anti-cancer Vaccines, Adoptive Cell Therapies and Immune-Checkpoint Inhibitors: A Novel Arsenal against Cancer

Message from the Guest Editors

Recent discoveries in cancer immunology have resulted in the incorporation of immunotherapeutic strategies for the treatment of various solid and hematologic malignancies. Immunotherapy is currently deemed to be the best way to improve prognosis for cancer patients in the near future. In this Special Issue, we provide an overview of clinical outcomes of immunotherapy in patients with advanced and/or metastatic malignancies as well as cover major clinical and scientific hurdles of cancer immunotherapy. Original research articles and reviews are welcome (note that systematic reviews must follow PRISMA guidelines). Research areas may include (but are not limited to) the following: anticancer vaccines, cancer immunotherapy, adoptive cellular therapy, T cell research, novel checkpoint inhibitors, NK cell therapy, systematic reviews with meta-analysis.

Guest Editors

Dr. Dmitrii Shek

Blacktown Clinical School, Western Sydney University, Marcel Crescent, Sydney, NSW 2148, Australia

Prof. Dr. Golo Ahlenstiel

Blacktown Clinical School, Western Sydney University, Marcel Crescent, Sydney, NSW 2148, Australia

Deadline for manuscript submissions

closed (5 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/163478

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).